These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies. Choi EH; Zhang F; Lu YJ; Malley R Clin Vaccine Immunol; 2016 Feb; 23(2):162-7. PubMed ID: 26677201 [TBL] [Abstract][Full Text] [Related]
23. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein. Yang HH; Mascuch SJ; Madoff LC; Paoletti LC Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225 [TBL] [Abstract][Full Text] [Related]
24. Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation. Pannaraj PS; Edwards MS; Ewing KT; Lewis AL; Rench MA; Baker CJ Vaccine; 2009 Jul; 27(33):4452-6. PubMed ID: 19490960 [TBL] [Abstract][Full Text] [Related]
25. Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women. Kwatra G; Adrian PV; Shiri T; Buchmann EJ; Cutland CL; Madhi SA Clin Microbiol Infect; 2015 Jun; 21(6):568.e13-21. PubMed ID: 25680313 [TBL] [Abstract][Full Text] [Related]
26. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Guttormsen HK; Liu Y; Paoletti LC Hum Vaccin; 2008; 4(5):370-4. PubMed ID: 18398304 [TBL] [Abstract][Full Text] [Related]
27. Seroprevalence of Opsonophagocytic Antibodies against Serotype Ia, Ib, II, III, and V Group B Streptococcus among Korean Population. Lee JH; Kim HW; Kim KH J Korean Med Sci; 2018 Apr; 33(16):e127. PubMed ID: 29651820 [TBL] [Abstract][Full Text] [Related]
28. Development of a multi-specificity opsonophagocytic killing assay. Nahm MH; Briles DE; Yu X Vaccine; 2000 Jun; 18(24):2768-71. PubMed ID: 10781864 [TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173 [TBL] [Abstract][Full Text] [Related]
30. Opsonophagocytic Killing Assay to Measure Anti-Group A Streptococcus Antibody Functionality in Human Serum. Wagstaffe H; Jones S; Johnson M; Goldblatt D Methods Mol Biol; 2022; 2414():373-386. PubMed ID: 34784047 [TBL] [Abstract][Full Text] [Related]
31. Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products. Kim HW; Lee JH; Cho HK; Lee H; Seo HS; Lee S; Kim KH J Korean Med Sci; 2017 May; 32(5):737-743. PubMed ID: 28378545 [TBL] [Abstract][Full Text] [Related]
32. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Kim KH; Yu J; Nahm MH Clin Diagn Lab Immunol; 2003 Jul; 10(4):616-21. PubMed ID: 12853394 [TBL] [Abstract][Full Text] [Related]
33. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Genschmer KR; Accavitti-Loper MA; Briles DE Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169 [TBL] [Abstract][Full Text] [Related]
34. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization. Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554 [TBL] [Abstract][Full Text] [Related]
35. Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against Salehi S; Hohn CM; Penfound TA; Dale JB mSphere; 2018 Dec; 3(6):. PubMed ID: 30567901 [TBL] [Abstract][Full Text] [Related]
36. Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus. Choi MJ; Noh JY; Jang AY; Cheong HJ; Kim WJ; Song DJ; Cho GJ; Oh MJ; Zhi Y; Seo HS; Song JY Hum Vaccin Immunother; 2020 Jun; 16(6):1338-1344. PubMed ID: 31687869 [TBL] [Abstract][Full Text] [Related]
37. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979 [No Abstract] [Full Text] [Related]
38. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833 [TBL] [Abstract][Full Text] [Related]
39. Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Melin M; Jarva H; Siira L; Meri S; Käyhty H; Väkeväinen M Infect Immun; 2009 Feb; 77(2):676-84. PubMed ID: 19047408 [TBL] [Abstract][Full Text] [Related]
40. Immune responses against group B Dhar N; Mohamed E; Kirstein F; Williams M; Dorasamy S; van Zyl P; Robertson MJ; Anderson T; Harden LM; Jardine K; Veeraraghavan B; Wilson S; Tippoo P; Madhi SA; Kwatra G iScience; 2023 Aug; 26(8):107380. PubMed ID: 37575182 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]